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Chlorambucil, 4-{4-[bis(2-chloroethyl)amino]phenyl}butyr-ic acid, is an alkylating agent of the nitrogen mustard group and is used as cytostatic drug in cancer therapy. The two reactive chloroethyl side chains readily react with the intracellular components such as proteins, phospholipids, and nucleic acids. The cytotoxicity of CHL is due to its ability to alkylate and modify DNA through the formation of either mono-or bifunctional adducts which interfere with gene expression and inhibit DNA synthesis. [1] [2] [3] In recent years, significant research efforts have been made in the development of various CHL derivatives with improved selectivity and high antitumor activity. [4, 5] In this regard, it will be beneficial to develop new CHL-based theranostic probes and utilize its antitumor properties in combination with magnetic resonance imaging (MRI) and therapy. MRI is a powerful diagnostic imaging modality and is superior over other imaging techniques due to its non-invasiveness, non-ionizing radiation, and high spatial resolution. [6] There is a continuing interest in the development of new MRI contrast agents (CAs) based on the macrocyclic ligand, 1,4,7,10-tetraazacyclododecane-1,4,7-tris-tert-butyl acetate (DO3A) due to its excellent chelating properties and high thermodynamic stability of the corresponding gadolinium (Gd) complex. [7, 8] DO3A-based macrocycles constitute an exciting class of molecules with a tremendous potential in biomedical applications as MRI contrast agents and/or | Kaur et al.
therapeutic radiopharmaceuticals. [9, 10] These molecules are versatile building blocks which can be tailored to accommodate targeting and therapeutic ligands allowing diverse applications in the emerging field of 'theranostics', the combination of therapeutics and diagnostics. [11, 12] With such methodology, we have focused our attention on the synthesis of a highly stable macrocyclic Gd(III)-DO3A-tyrosine chelate and its facile conjugation with CHL to develop a novel MRI theranostic conjugate. This attractive chelate-drug ensemble provides a unique platform with the diagnostic (Gd-DO3A) and therapeutic (CHL) components linked via tyrosine in a single molecule. Tyrosine is a suitable scaffold and a potential synthetic precursor possessing chemical versatility and facile reactivity for covalent conjugation. It also offers reactive side chains which can be used for the selective functionalization of the macrocyclic ligand via simple and straight forward procedures. [13, 14] These facts provided us strong motivation to investigate the possibility of coupling DO3A macrocycle to chlorambucil drug through tyrosine which could function as a linker as well as a targeting vector to improve the binding affinity and specificity of the resulting hybrid.
To this end, we report here the straightforward synthetic routes for the preparation of a neutral Gd(III) complex of (4-{2-[2-(4-{4-[bis-(2-chloroethyl)amino]-phenyl}-butyrylamino)-3-(4-hydroxyphenyl) propionyl-amino]-ethyl-10-tert-butoxycarbonylmethyl-7-carboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid, DO3A-TR-CHL for use as a diagnostic anticancer agent. The resulting ligand and its Gd(III) complex have been characterized by NMR and MS and relaxation parameters of the Gd(III)-DO3A-TR-CHL have been investigated. The physicochemical parameters such as lipophilicity and stability have been evaluated for the Gd(III) complex by octanol-water partition coefficient method and potentiometric titrations, respectively. The in vitro cytotoxic activities of the conjugates DO3A-TR-CHL; Gd(III)-DO3A-TR-CHL and Gd(III)-DO3A have been evaluated using MTT assay against A549 (lung carcinoma cells), HeLa (Human epithelial carcinoma cells) and HEK (human embryonic kidney cells) and have been compared with the parent nitrogen mustard.
| METHODS AND MATERIALS

| Chemistry
All reagents and solvents of analytical grade were obtained commercially and were used as such unless noted otherwise. 1,4,7,10-tetraazacyclododecane was purchased from CheMatech (Dijon, France). Air-sensitive reactions were conducted under nitrogen atmosphere in oven-dried glass apparatus. All reactions were monitored by thin-layer chromatography (TLC) on Merck silica gel plates (60GF-254) and visualized with UV light. Column chromatography was carried out using silica MN60 (60-200 mm; Merck) for purification of final products. 1 
| Synthesis of 2-amino-N-(2-bromoethyl)-
3-(4-hydroxyphenyl)-propionamide (2)
To a solution of compound 1 in dry DCM (20 mL) was added neat TFA (4 mL) at 0 °C and the mixture was stirred for 4 h. The reaction mixture was allowed to cool to room temperature and stirred for an additional 1 h. After the completion of the reaction, the reaction mixture was extracted with water, saturated aqueous sodium bicarbonate solution (2 × 30 mL), and brine (2 × 30 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure. The crude product was dissolved in DCM and evaporated several times to remove residual TFA. 45 mmol) was added to the above reaction mixture and heated to 60 °C. The reaction was stirred at 60 °C for 10 h. The reaction mixture was allowed to cool to room temperature and filtered and the filtrate was evaporated to yield a crude product that was washed with brine (3 × 30 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to yield compound 4 as a brown oily product in 64.3% yield. 
| Synthesis of (4-{2-[2-amino
| Synthesis of (4-{2-[2-(4-{4-[bis-(2-chloroethyl)-amino]-phenyl}-butyrylamino)-3-(4-hydroxy-phenyl)-propionylamino]-ethyl}-1, 4,7-tri(carbobutoxymethane)-1,4,7,10-tetraazacyclododecane (5)
To a solution of compound 4 (0.40 g, 0.55 mmol) and Et 3 N (0.08 g, 0.83 mmol) in dry DMF (20 mL) was added chlorambucil N-hydroxysuccinimidyl ester (0.33 g, 0.83 mmol) at room temperature under nitrogen atmosphere. The reaction mixture was stirred for 24 h. After completion of the reaction, the reaction mixture was washed with water and brine (3 × 30 mL). The combined organic extracts were dried over anhydrous sodium sulfate and evaporated to yield the crude product which was purified by column chromatography on a silica gel (eluent: DCM-MeOH: 8/2) to give final compound 5 as a yellow oily product in 72% yield. Compound 5 (0.40 g, 0.47 mmol) was dissolved in neat TFA (3 mL) at 0 °C and stirred for 4 h. The reaction mixture was allowed to cool to room temperature and stirred for an additional 10 h. The solvent was evaporated under reduced pressure and the product was washed with chloroform (2 × 20 mL). After trituration with cold ether, the compound was precipitated and dried to obtain the final product as a brown solid in 75% yield. 
| Synthesis of (4-{2-[2-(4-{4-[bis-(2-
chloroethyl
| Synthesis of Gd(III) complex of DO3A-TR-CHL (7)
To a stirred aqueous solution of ligand DO3A-TR-CHL (0.20 g, 0.23 mmol), 1M NaOH was added dropwise until pH 7.0 was attained. GdCl 3 .6H 2 O (0.08 g, 0.23 mmol) was added to the above reaction mixture and the reaction was heated at 60 °C for 16 h. The pH of the reaction was periodically checked and adjusted to 7.0. After 16 h, the reaction mixture was allowed to cool to room temperature and was passed through Chelex 100 to trap free Gd ions. Gd-loaded complex was eluted and absence of free Gd(III) was checked by xylenol orange indicator. The desired fraction was lyophilized and final product was obtained as a white solid. 
| Potentiometric titrations
The protonation constants of DO3A-TR-CHL ligand and the stability constant of the Gd(III) complex were determined by pH potentiometric titrations performed with an automatic titration system consisting of a Metrohm 713 pH meter equipped with a Metrohm A.60262.100 glass electrode, 800 Dosino autoburet. Titrations were carried out at 25 ± 0.1 °C, at an ionic strength I(NMe 4 Cl) = 0.1 mol/dm 3 and in the pH range of 2-12 for the determination of protonation constants. The protonation constants of the ligand were determined by titrating DO3A-TR-CHL with tetramethylammonium hydroxide. The stability constant of the Gd(III) complex was determined by direct pH potentiometric titration at 1:1 Gd(III)-to-ligand (0.002 m) concentration ratios. A minimum of two duplicate measurements were taken. The protonation and stability constants were evaluated using titration data using the program Tiamo 2.0. The stability and protonation constants of the Gd(III) complex formed with the ligand are defined by Eqns (1) and (2) [15] :
| Lipophilicity measurements
The partition coefficient of Gd(III)-DO3A-TR-CHL was determined as the ratio of the concentration of the complex in octanol and concentration of the complex in the aqueous phase given by the following equation:
The logarithm of the partition coefficient is referred to as the log P value. The 'shake flask' method was used for the determination of log P. [16] Water saturated with octanol and octanol saturated with water were used in the experiments. A 1:1 volume ratio was used for the partitioning of the solution with the Gd(III) complex. 0.5 mL of a 100 μM solution of the Gd(III) complex was added to 0.5 mL of the saturated phase of 1-octanol in a 2-mL Eppendorf tube. The mixtures were vigorously shaken on a shaker long enough to reach equilibrium (~1 h). After equilibration, the mixtures were centrifuged (20 min at 479 x g) to achieve good separation between the two phases. The concentration of the Gd(III) complex was determined in each phase using standard UV curves and the partition coefficient was calculated and compared to Gd(III)-DO3A.
| Cell culture
Monolayer cultures of HeLa cells were maintained in RPMI 1640 (with l-glutamine and NaHCO 3 ) culture medium (Sigma) containing 10% fetal calf serum, 50 μg∕mL penicillin, and 0.05 g⁄mL streptomycin in a humidified CO 2 incubator (5% CO 2 , 95% air). A549 cells and HEK 293 cells were maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco), 5 units/mL penicillin, and 0.05 g⁄mL streptomycin in a humidified CO 2 incubator (5% CO 2 , 95% air).
| MTT assay
Cytotoxicity was determined using the MTT (3-(4,5-dimet hyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Exponentially growing A549, HeLa, and HEK 293 cells were plated in a 96-well microtiter plate at a uniform cell density of 4 × 10 3 cells/well 24 h before treatment. The DMEM or RPMI growth medium was removed, and cells were treated with compound 6, its Gd(III) complex (7), and Gd(III)-DO3A at different concentrations (0.01-1.0 mm) for 24 h at 37 °C. Chlorambucil was used as a positive control. Cells treated with medium only served as a negative control group. After treatment, cells were incubated with MTT (0.5 mg/mL) for 4 h at 37 °C. The medium was then carefully removed by aspiration, and the cells were lysed in 200 μL of DMSO to dissolve the formazan crystals. The enzymatic reduction of MTT to formazan crystals was quantified by the optical density measured at 570 nm with 630 nm as a reference filter. All assays were done in triplicate and results have been expressed as the mean ± SD. The IC 50 was calculated for each treatment from dose-response curves in which mean viability values were plotted against the conjugate concentrations.
(1)
| RESULTS AND DISCUSSION
| Chemistry
The bifunctional DO3A chelate and its Gd(III) complex, each abbreviated as DO3A-TR-CHL and Gd(III)-DO3A-TR-CHL, were prepared according to the synthetic procedure described in Scheme 1. N-(tert-butoxycarbonyl)-l-tyrosine methyl ester was used as the starting material for the synthesis of the bifunctional chelate. The choice of methyl ester of tyrosine not only gave the advantage of enhanced solubility in organic solvents but also minimized the likelihood of possible side reactions in subsequent coupling reactions. The intermediate compound, (2), was obtained by reacting 2-bromoethylamine hydrobromide with N-(tert-butoxycarbonyl)-l-tyrosine methyl ester at room temperature. N-Boc group removal of compound 1 under common reaction conditions (TFA) quantitatively released tyrosine conjugate 2. DO3A (3) was synthesized according to a literature procedure. [17] DO3A upon alkylation with compound 2 in the presence of potassium carbonate afforded the corresponding tyrosine-coupled DO3A ligand (DO3A-TR), 4, in quantitative yield and sufficient purity. The synthesis of compound 4 was confirmed by the presence of proton signals typical for the macrocyclic ring in the δ 3.82-2.64 ppm range in 1 H NMR and by the presence of the carbonyl peak (-CONH) at 172.07 ppm in 13 C NMR spectrum. The predominant mass peak at m/z 748.5 in ESI-MS spectrum further supported the successful formation of conjugate 4. Subsequently, the bioconjugate ligand 5 was synthesized by the reaction of chlorambucil N-hydroxysuccinimidyl ester with ligand 4 in the presence of triethylamine in DMF. 13 C NMR spectrum of ligand 5 depicted characteristic signals at 171.20 and 170.80 ppm corresponding to the carbonyl group and amide group, respectively. ESI-MS peak at m/z 1007.9 further validated the conjugation of CHL to the macrocyclic ring and synthesis of conjugate 5. The final step involved deprotection of the tert-butyl groups with TFA at 0 °C yielding the desired compound DO3A-TR-CHL (6) in 75% yield (Scheme 2). For MRI studies, a Gd complex of DO3A-TR-CHL was prepared with GdCl 3 .6H 2 O in the stoichiometric ratio of 1:1. Elution of the reaction mixture through Chelex 100 helped to trap free lanthanide ion and provided the neat Gd(III) complex as the eluent. The absence of free Gd(III) was checked by xylenol orange indicator. Gd(III)-DO3A-TR-CHL (7) was characterized by MS and isotopic pattern of seven peaks confirmed the complexation of the final ligand with Gd(III). All intermediates and the final compounds were characterized by 1 H, 13 C NMR, and MS (Supporting Information). /s) [18] which suggests that the relaxivity value increases with increase in molecular weight of CA. The transverse relaxivity (r 2 ) of the Gd(III) complex was found to be 10.81 mm −1 /s (MSE sequence). The measured relaxivities arise from the exchange between the co-ordinated water molecules and the surrounding water molecules in solution.
| MRI: relaxometric studies
To evaluate the imaging potential of the CA, phantom experiments with dilution series were performed using a clinical 3 T MRI scanner. A clearly observable positive contrast was detected in T 1 -weighted MRI images of the Gd(III) complex with sufficient enhancement of the contrast at low concentrations (0.6 mm). In the images, intensity was brighter in comparison with the one taken in the absence of any contrast agent. The above results are highly promising and further expand the suitability of the DO3A-chlorambucil conjugate for MRI applications. [19, 20] 
| Protonation and thermodynamic stability constants
The protonation constants of DO3A-TR-CHL ligand and the stability constant of the Gd(III) complex obtained by potentiometric titrations are summarized in Table 1 . A pH potentiometric titration of DO3A-TR-CHL ligand over 2-12 pH range gave three protonation constants which are likely to be associated with the presence of three carboxylic acid groups in the structure.
The stability constant of Gd(III)-DO3A-TR-CHL was obtained almost in the same range as that of Gd(III)-DO3A [21] and the data indicated sufficiently high thermodynamic stability of the Gd(III) complex of DO3A-TR-CHL ligand to be used as a safe MRI CA for biomedical applications. 
| Lipophilicity measurements: octanolwater partition coefficient
Octanol-water partition coefficients (log P) were measured to determine the lipophilicity of the Gd(III) complex of DO3A-TR-CHL ligand. Gd(III)-DO3A-TR-CHL (log P = −0.59) was more hydrophobic than Gd(III)-DO3A (log P = −2.96), owing to the presence of the lipophilic chlorambucil drug in the structural framework. The data revealed an intermediate hydrophobicity of the Gd(III) complex, thereby suggesting favoured cellular permeability and uptake of the developed MRI probe in the tumor cells.
| MTT assay: in vitro cytotoxicity
The cytotoxic activities of the DO3A-TR-CHL conjugate (6); Gd(III)-DO3A-TR-CHL complex (7) and Gd(III)-DO3A were evaluated in vitro against different cell lines such as A549, HeLa, and HEK 293 by MTT assay in comparison with CHL. As shown by the MTT assays (Figure 2 ), the Gd(III) complex showed dose-dependent toxicity and better antitumor activity against A549 tumor cells, with an IC 50 value of 0.11 mm, compared to parent drug, CHL (IC 50 = 0.27 mm). The probe exhibited a significant reduction in cell viability in A549 (0.11% ± 0.03%) and HeLa (0.19% ± 0.11%) tumor cell lines at 1.0 mm concentration after 24-h treatment, while free CHL displayed a weak activity with a cell survival in the range of 62.5%-74.8% on above cell lines. The IC 50 value for HeLa cells was 0.18 mm, while the same concentration of the Gd(III) complex rendered no significant toxicity in normal HEK 293 cells. In contrast, CHL showed progressive toxicity on normal HEK 293 cells, with a maximum cytocidal activity of 70% (30% cell survival) at 1 mm concentration and 24 h postincubation (Supporting Information). The above observations clearly indicate that the CA possesses higher antiproliferative potency and preferential selectivity toward tumor cells than normal cells. This improvement in potency (as compared to parent mustard) could be correlated with the preferential retention of the probe in tumor cells than in normal cells due to an upregulated transport of tyrosine to support high-level protein synthesis in tumor cells. [22] These results suggest that the developed probe fulfills the requirements of an efficient theranostic agent for use in cancer imaging by MRI, while acting as a platform for tumor therapy.
| CONCLUSIONS
In summary, we have successfully reported the chemical synthesis of a bifunctional DO3A chelate of chlorambucil and its Gd complex using a chelate-drug ensemble approach. The usage of chlorambucil-based DO3A conjugate is a relatively new and exciting approach for multifunctional therapy and molecular imaging of human cancers. The herein utilized bioconjugation strategy enables efficient coupling of the chemotherapeutic drug chlorambucil to the tyrosine-functionalized DO3A macrocyclic ligand. The high in vitro relaxivity of [Gd(DO3A-TR-CHL)] makes it a promising candidate for use as a MRI CA. Biological evaluation revealed that the Gd(III) complex exhibited better antitumor activity against A549 and HeLa tumor cell lines than the parent drug. Hence, the present study provides a new insight of the chlorambucil-conjugated DO3A derivative serving as a drug like MRI theranostic. Taken together, these results provide the basis for further in vitro and in vivo evaluation of the compound which is under progress.
